ACAD
NASDAQACADIA Pharmaceuticals Inc.
Price$21.56-1.81 (-7.74%)
2026-03-042026-06-05
News · 26 weeks54-18%
2025-12-142026-06-07
Mix4190d
- Insider25(61%)
- Other8(20%)
- SEC Filings4(10%)
- Earnings2(5%)
- Analyst1(2%)
- Leadership1(2%)
Latest news
25 items- INSIDERDirector Baker Bros. Advisors Lp was granted 37,244 shares (SEC Form 4)4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
- INSIDERDirector Harrigan Edmund converted options into 8,107 shares, increasing direct ownership by 23% to 43,148 units (SEC Form 4)4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
- INSIDERDirector Ndu Adora converted options into 8,107 shares, increasing direct ownership by 33% to 32,908 units (SEC Form 4)4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
- INSIDERDirector Daly James M converted options into 8,107 shares, increasing direct ownership by 201% to 12,148 units (SEC Form 4)4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
- INSIDERDirector Brege Laura converted options into 8,107 shares, increasing direct ownership by 54% to 23,202 units (SEC Form 4)4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
- INSIDERDirector Garofalo Elizabeth A. converted options into 8,107 shares, increasing direct ownership by 32% to 33,489 units (SEC Form 4)4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
- INSIDERDirector Poole Jonathan converted options into 2,010 shares (SEC Form 4)4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
- SECACADIA Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Leadership Update8-K - ACADIA PHARMACEUTICALS INC (0001070494) (Filer)
- INSIDERPRINCIPAL ACCOUNTING OFFICER Kihara James sold $114,393 worth of shares (5,401 units at $21.18), decreasing direct ownership by 18% to 24,509 units (SEC Form 4)4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
- SECSEC Form 10-Q filed by ACADIA Pharmaceuticals Inc.10-Q - ACADIA PHARMACEUTICALS INC (0001070494) (Filer)
- SECACADIA Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ACADIA PHARMACEUTICALS INC (0001070494) (Filer)
- PRAcadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance- First quarter DAYBUE® GAAP net sales of $101 million, up 20% year-over-year; successful launch of DAYBUE STIX underway - First quarter NUPLAZID® GAAP net sales of $167 million, up 6% year-over-year on a non-GAAP adjusted basis - Reaffirms expectation for topline results from the Phase 2 remlifanserin study in Alzheimer's disease psychosis between August and October 2026 Acadia Pharmaceuticals Inc. (NASDAQ:ACAD), today announced its financial results for the first quarter ended March 31, 2026. "Acadia delivered a solid first quarter of 2026 with total revenues of $268 million, driven by a strong start from DAYBUE, which generated sales of $101 million," said Catherine Owen Adams, C
- INSIDERPRINCIPAL ACCOUNTING OFFICER Kihara James converted options into 2,596 shares and sold $29,024 worth of shares (1,332 units at $21.79) as part of a pre-agreed trading plan, increasing direct ownership by 5% to 29,129 units (SEC Form 4) to satisfy withholding tax4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
- INSIDEREVP, CHIEF FINANCIAL OFFICER Schneyer Mark C. sold $76,396 worth of shares (3,506 units at $21.79) as part of a pre-agreed trading plan and converted options into 6,815 shares, increasing direct ownership by 5% to 66,145 units (SEC Form 4) to cover withholding tax4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
- FDAFDA Approval for NUPLAZID issued to ACADIA PHARMS INCSubmission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-16) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 05/04/2026. Application Category: NDA, Application Number: 210793, Application Classification: Labeling
- PRAcadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished CareerAcadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the planned retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development. Dr. Thompson has decided to retire for personal reasons and informed Acadia of her plans. She will continue in her role as Head of Research and Development until a successor is appointed. After her retirement, Acadia plans to retain Dr. Thompson as a consultant through at least the end of 2026 to ensure scientific and leadership continuity through the planned readout of the Phase 2 clinical study of remlifanserin in Alzheimer's disease psychosis (ADP) and into early Phase 3 clinical study execution. Acadia has initiated a search for a new He
- FDAFDA Approval for NUPLAZID issued to ACADIA PHARMS INCSubmission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-16) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 04/27/2026. Application Category: NDA, Application Number: 207318, Application Classification: Efficacy
- FDAFDA Approval for NUPLAZID issued to ACADIA PHARMS INCSubmission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-14) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 04/27/2026. Application Category: NDA, Application Number: 210793, Application Classification: Efficacy
- PRAcadia Pharmaceuticals to Participate at Upcoming Investor ConferencesAcadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will participate at two upcoming investor conferences: BofA Securities 2026 Health Care Conference Fireside Chat: Tuesday, May 12, 2026 at 4:20 p.m. Pacific Time in Las Vegas, NV 2026 RBC Capital Markets Global Healthcare Conference Fireside Chat: Tuesday, May 19, 2026 at 9:00 a.m. Eastern Time in New York, NY Live webcasts will be accessible on the company's website, acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation. About Acadia Pharmaceuticals Acadia is committed to turning scientific promise into meaningful i
- SECSEC Form DEF 14A filed by ACADIA Pharmaceuticals Inc.DEF 14A - ACADIA PHARMACEUTICALS INC (0001070494) (Filer)
- PRAcadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual MeetingAcadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will present multiple original data presentations spanning its portfolio at the 2026 American Academy of Neurology (AAN) Annual Meeting, taking place April 18–22, 2026 in Chicago, IL. The Company will present real-world data from a sub-group analysis of the ongoing, Phase 4, prospective, observational, open-label LOTUS study evaluating the benefits and tolerability of DAYBUE® (trofinetide) in adults with Rett syndrome in routine clinical practice. In support of NUPLAZID® (pimavanserin) in Parkinson's disease psychosis (PDP), Acadia will present exploratory analyses evaluating heterogeneity in treatment response trajectories
- PRAcadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026Company to host conference call and webcast on Wednesday, May 6, 2026, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will report first quarter 2026 financial results on Wednesday, May 6, 2026, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on May 6, 2026, at 4:30 p.m. Eastern Time. The conference call will be available on Acadia's website, acadia.com under the investors section and will be archived there until August 15, 2026. The conference call may also be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in numb
- INSIDERSEC Form 4 filed by Schneyer Mark C.4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
- INSIDERSEC Form 4 filed by Kihara James4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
- PRAcadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome-- DAYBUE STIX is a new powder formulation of trofinetide -- Recently published expert consensus recognizes trofinetide as part of the standard of care for Rett syndrome and highlights the importance of flexible, patient-centered treatment approaches Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced DAYBUE® STIX (trofinetide) for oral solution, a dye- and preservative-free powder formulation of trofinetide, is now broadly available in the United States for the treatment of Rett syndrome in adults and pediatric patients two years of age and older. The new formulation, approved by the U.S. Food and Drug Administration (FDA) in December 2025, is bioequivalent to the original DAYBUE
ACAD FAQ
7 questionsWhat does ACADIA Pharmaceuticals Inc. do?
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor...Where does ACAD stock trade?
ACADIA Pharmaceuticals Inc. (ACAD) is listed on NASDAQ.What sector and industry is ACAD in?
ACADIA Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did ACADIA Pharmaceuticals Inc. go public?
ACADIA Pharmaceuticals Inc. (ACAD) completed its IPO in 1985.What are analysts saying about ACAD?
ACADIA Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from BofA Securities: Buy with a $2900.00 price target on 2026-03-25. Recent price targets range from $2000.00 to $3500.00.What companies are similar to ACAD?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ACAD side-by-side with any of them on Quantisnow.How can I track ACAD on Quantisnow?
Quantisnow aggregates ACADIA Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ACAD to receive live email and push alerts on every new disclosure.